The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Sustained Release Innovation for HIV (SRI) (R61/R33 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate the development of new and innovative sustained/extended release drugs and drug delivery systems (DDS) that can achieve extended durations (months to years) of HIV prevention in at-risk individuals. This FOA requires an industry partner, milestones linked to Go/No-Go decisions and year 5 funding requires submission of a pre-IND application to the FDA.
- Letter of Intent Due Date(s): October 30, 2018
- Application Due Date(s): November 30, 2018
- AIDS Application Due Date(s): November 30, 2018
RFA-AI-18-006 Expiration Date December 1, 2018